CENPL

Summary

CENPL (centromere protein L, HGNC:17879) is a protein-coding gene on chromosome 1q25.1, encoding Centromere protein L (Q8N0S6). Component of the CENPA-CAD (nucleosome distal) complex, a complex recruited to centromeres which is involved in assembly of kinetochore proteins, mitotic progression and chromosome segregation. It is a selective cancer dependency (DepMap: 38.7% of cell lines).

CENPL is a subunit of a CENPH (MIM 605607)-CENPI (MIM 300065)-associated centromeric complex that targets CENPA (MIM 117139) to centromeres and is required for proper kinetochore function and mitotic progression (Okada et al., 2006) [PubMed 16622420].

Source: NCBI Gene 91687 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 66 total
• Cancer dependency (DepMap): dependent in 38.7% of screened cell lines
• MANE Select transcript: NM_001387287

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17879
Approved symbol	CENPL
Name	centromere protein L
Location	1q25.1
Locus type	gene with protein product
Status	Approved
Aliases	dJ383J4.3, FLJ31044
Ensembl gene	ENSG00000120334
Ensembl biotype	protein_coding
OMIM	611503
Entrez	91687

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 14 protein_coding, 6 protein_coding_CDS_not_defined

ENST00000345664, ENST00000356198, ENST00000367710, ENST00000460816, ENST00000479159, ENST00000484920, ENST00000493233, ENST00000495275, ENST00000496683, ENST00000682279, ENST00000893543, ENST00000893544, ENST00000920091, ENST00000920092, ENST00000920093, ENST00000920094, ENST00000920095, ENST00000920096, ENST00000966256, ENST00000966257

RefSeq mRNA: 13 — MANE Select: NM_001387287 NM_001127181, NM_001171182, NM_001387284, NM_001387285, NM_001387286, NM_001387287, NM_001387288, NM_001387289, NM_001387290, NM_001387291, NM_001387292, NM_001387293, NM_033319

CCDS: CCDS30938, CCDS44277

Canonical transcript exons

ENST00000682279 — 6 exons

Exon	Start	End
ENSE00001399955	173823926	173824019
ENSE00001422174	173799550	173800519
ENSE00003582687	173807267	173807518
ENSE00003586960	173802963	173803505
ENSE00003683916	173811132	173811306
ENSE00003918516	173824212	173824883

Expression profiles

Bgee: expression breadth ubiquitous, 211 present calls, max score 88.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.3588 / max 102.4431, expressed in 1679 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
15957	3.0417	1303
15956	1.8725	883
15955	1.2736	716
15953	0.9568	606
15958	0.6186	300
15954	0.5955	385

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	88.95	gold quality
ventricular zone	UBERON:0003053	88.06	gold quality
secondary oocyte	CL:0000655	86.39	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.97	gold quality
ganglionic eminence	UBERON:0004023	82.71	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.87	gold quality
endothelial cell	CL:0000115	80.56	silver quality
bone marrow	UBERON:0002371	79.69	gold quality
stromal cell of endometrium	CL:0002255	79.23	gold quality
adult organism	UBERON:0007023	78.36	gold quality
bone marrow cell	CL:0002092	76.42	gold quality
calcaneal tendon	UBERON:0003701	76.09	gold quality
buccal mucosa cell	CL:0002336	75.67	gold quality
trabecular bone tissue	UBERON:0002483	74.98	gold quality
vermiform appendix	UBERON:0001154	74.94	gold quality
smooth muscle tissue	UBERON:0001135	74.64	gold quality
testis	UBERON:0000473	74.51	gold quality
right testis	UBERON:0004534	74.49	gold quality
lymph node	UBERON:0000029	74.21	gold quality
amniotic fluid	UBERON:0000173	74.06	gold quality
hindlimb stylopod muscle	UBERON:0004252	73.80	gold quality
rectum	UBERON:0001052	73.74	gold quality
left testis	UBERON:0004533	73.72	gold quality
adrenal tissue	UBERON:0018303	73.63	gold quality
islet of Langerhans	UBERON:0000006	73.61	gold quality
tendon	UBERON:0000043	73.08	gold quality
epithelial cell of pancreas	CL:0000083	72.83	silver quality
muscle of leg	UBERON:0001383	72.35	gold quality
thymus	UBERON:0002370	72.29	gold quality
gastrocnemius	UBERON:0001388	72.15	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.75

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting CENPL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-12135	98.99	70.26	1814
HSA-MIR-511-5P	98.97	70.94	2268
HSA-MIR-1304-5P	98.90	68.58	1054
HSA-MIR-3146	98.85	66.77	601
HSA-MIR-222-5P	98.75	69.17	1242
HSA-MIR-4742-3P	98.73	69.82	1803
HSA-MIR-203B-3P	97.82	66.27	979
HSA-MIR-22-5P	97.67	68.92	1355
HSA-MIR-8055	97.62	66.09	1023
HSA-MIR-512-5P	97.47	66.48	591
HSA-MIR-3667-5P	97.16	64.87	591
HSA-MIR-101-5P	96.84	65.66	649
HSA-MIR-6734-5P	95.70	65.56	950

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 38.7% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• Study demonstrate that the CENP-L-N complex plays a crucial role at the core of the 16-subunit Constitutive Centromere-Associated Network through interactions with CENP-C and CENP-H-I-KM. (PMID:26698661)
• High mRNA Expression of CENPL and Its Significance in Prognosis of Hepatocellular Carcinoma Patients. (PMID:34457090)
• Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma. (PMID:34607313)
• Overexpression of CENPL mRNA potentially regulated by miR-340-3p predicts the prognosis of pancreatic cancer patients. (PMID:36572856)
• CENPL accelerates cell proliferation, cell cycle, apoptosis, and glycolysis via the MEK1/2-ERK1/2 pathway in hepatocellular carcinoma. (PMID:37914022)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cenpl	ENSDARG00000038802
mus_musculus	Cenpl	ENSMUSG00000026708
rattus_norvegicus	Cenpl	ENSRNOG00000038789

Protein

Protein identifiers

Centromere protein L — Q8N0S6 (reviewed: Q8N0S6)

Alternative names: Interphase centromere complex protein 33

All UniProt accessions (1): Q8N0S6

UniProt curated annotations — full annotation on UniProt →

Function. Component of the CENPA-CAD (nucleosome distal) complex, a complex recruited to centromeres which is involved in assembly of kinetochore proteins, mitotic progression and chromosome segregation. May be involved in incorporation of newly synthesized CENPA into centromeres via its interaction with the CENPA-NAC complex.

Subunit / interactions. Component of the CENPA-CAD complex, composed of CENPI, CENPK, CENPL, CENPO, CENPP, CENPQ, CENPR and CENPS. The CENPA-CAD complex interacts with the CENPA-NAC complex, at least composed of CENPA, CENPC, CENPH, CENPM, CENPN, CENPT and CENPU.

Subcellular location. Nucleus. Chromosome. Centromere.

Similarity. Belongs to the CENP-L/IML3 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8N0S6-1	1	yes
Q8N0S6-2	2
Q8N0S6-3	3

RefSeq proteins (13): NP_001120653, NP_001164653, NP_001374213, NP_001374214, NP_001374215, NP_001374216, NP_001374217, NP_001374218, NP_001374219, NP_001374220, NP_001374221, NP_001374222, NP_201576 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR025204	CENP-L	Family

Pfam: PF13092

UniProt features (37 total): strand 18, helix 10, modified residue 3, splice variant 3, chain 1, turn 1, sequence variant 1

Structure

Experimental structures (PDB)

12 structures.

PDB	Method	Resolution (Å)
28OP	ELECTRON MICROSCOPY	2.7
7R5S	ELECTRON MICROSCOPY	2.83
7PKN	ELECTRON MICROSCOPY	3.2
7XHO	ELECTRON MICROSCOPY	3.29
9TAW	ELECTRON MICROSCOPY	3.54
7XHN	ELECTRON MICROSCOPY	3.71
9TAX	ELECTRON MICROSCOPY	4.5
7R5V	ELECTRON MICROSCOPY	4.55
7QOO	ELECTRON MICROSCOPY	4.6
7YYH	ELECTRON MICROSCOPY	8.9
7YWX	ELECTRON MICROSCOPY	12
9TAY	ELECTRON MICROSCOPY	15.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N0S6-F1	83.44	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 39, 43, 53

Function

Pathways and Gene Ontology

Reactome pathways

21 pathways

ID	Pathway
R-HSA-141444	Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
R-HSA-2467813	Separation of Sister Chromatids
R-HSA-2500257	Resolution of Sister Chromatid Cohesion
R-HSA-5663220	RHO GTPases Activate Formins
R-HSA-606279	Deposition of new CENPA-containing nucleosomes at the centromere
R-HSA-68877	Mitotic Prometaphase
R-HSA-9648025	EML4 and NUDC in mitotic spindle formation
R-HSA-141424	Amplification of signal from the kinetochores
R-HSA-162582	Signal Transduction
R-HSA-1640170	Cell Cycle
R-HSA-194315	Signaling by Rho GTPases
R-HSA-195258	RHO GTPase Effectors
R-HSA-2555396	Mitotic Metaphase and Anaphase
R-HSA-68882	Mitotic Anaphase
R-HSA-68886	M Phase
R-HSA-69278	Cell Cycle, Mitotic
R-HSA-69618	Mitotic Spindle Checkpoint
R-HSA-69620	Cell Cycle Checkpoints
R-HSA-73886	Chromosome Maintenance
R-HSA-774815	Nucleosome assembly
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 152 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, CAFFAREL_RESPONSE_TO_THC_UP, FISCHER_G2_M_CELL_CYCLE, DODD_NASOPHARYNGEAL_CARCINOMA_UP, FISCHER_DREAM_TARGETS, BURTON_ADIPOGENESIS_PEAK_AT_24HR, REACTOME_CELL_CYCLE_CHECKPOINTS, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, DURCHDEWALD_SKIN_CARCINOGENESIS_UP, CAFFAREL_RESPONSE_TO_THC_24HR_5_DN, NUYTTEN_EZH2_TARGETS_DN, GOCC_CHROMOSOMAL_REGION, MARSON_BOUND_BY_FOXP3_STIMULATED, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, MARSON_BOUND_BY_E2F4_UNSTIMULATED

GO Biological Process (1): chromosome segregation (GO:0007059)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): inner kinetochore (GO:0000939), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), chromosome, centromeric region (GO:0000775), chromosome (GO:0005694)

Reactome top-level categories

Rollup of top-14 pathways:

Category	Pathways
Cell Cycle	3
Mitotic Prometaphase	2
M Phase	2
Amplification of signal from the kinetochores	1
Mitotic Anaphase	1
RHO GTPase Effectors	1
Nucleosome assembly	1
Mitotic Spindle Checkpoint	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Mitotic Metaphase and Anaphase	1
Cell Cycle, Mitotic	1
Cell Cycle Checkpoints	1
Chromosome Maintenance	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cell cycle process	1
binding	1
kinetochore	1
protein-containing complex	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
chromosomal region	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1054 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CENPL	CENPK	Q9BS16	993
CENPL	CENPH	Q9H3R5	988
CENPL	CENPO	Q9BU64	984
CENPL	CENPI	Q92674	979
CENPL	CENPQ	Q7L2Z9	971
CENPL	CENPP	Q6IPU0	962
CENPL	CENPN	Q96H22	960
CENPL	ITGB3BP	Q13352	956
CENPL	CENPM	Q9NSP4	937
CENPL	CENPT	Q96BT3	930
CENPL	CENPC	Q03188	928
CENPL	CENPS	Q8N2Z9	925
CENPL	CENPA	P49450	921
CENPL	CENPU	Q71F23	906
CENPL	CENPW	Q5EE01	787

IntAct

21 interactions, top by confidence:

A	B	Type	Score
ITGB3BP	CENPU	psi-mi:“MI:0914”(association)	0.710
CENPL	FAM9B	psi-mi:“MI:0915”(physical association)	0.560
RRP8	NVL	psi-mi:“MI:0914”(association)	0.530
SCN3B	ABCC5	psi-mi:“MI:0914”(association)	0.530
CENPH	ITGB3BP	psi-mi:“MI:0914”(association)	0.530
CENPH	PSMD11	psi-mi:“MI:0914”(association)	0.530
CENPK	DHRS12	psi-mi:“MI:0914”(association)	0.530
GORASP1	PPP6R2	psi-mi:“MI:0914”(association)	0.530
CENPL	ICK	psi-mi:“MI:0915”(physical association)	0.400
CENPL	RBM42	psi-mi:“MI:0915”(physical association)	0.400
CENPL	JMJD6	psi-mi:“MI:0915”(physical association)	0.370
Cenph	CENPX	psi-mi:“MI:0914”(association)	0.350
GORASP1	CLASP2	psi-mi:“MI:0914”(association)	0.350
PRKRA	MPHOSPH10	psi-mi:“MI:0914”(association)	0.350
RPLP0	MPHOSPH10	psi-mi:“MI:0914”(association)	0.350
CENPL	RPL13	psi-mi:“MI:0914”(association)	0.350
TMED5	DGAT1	psi-mi:“MI:0914”(association)	0.350

BioGRID (31): FAM9B (Two-hybrid), ICK (Affinity Capture-MS), CENPL (Affinity Capture-MS), CENPL (Affinity Capture-MS), CENPL (Affinity Capture-MS), CENPL (Affinity Capture-MS), CENPL (Affinity Capture-MS), ICK (Affinity Capture-MS), CENPL (Affinity Capture-MS), CENPL (Affinity Capture-MS), CENPL (Affinity Capture-MS), CENPL (Affinity Capture-MS), CENPL (Affinity Capture-MS), CENPK (Affinity Capture-MS), CENPU (Affinity Capture-MS)

ESM2 similar proteins: A4FV97, A6NFN9, F6RRD7, O60934, O96028, P14629, P38432, P78345, Q05CL8, Q12789, Q28G87, Q32LC1, Q3MHN7, Q3U3S3, Q3US16, Q496Z9, Q4AC94, Q4G0J3, Q4R627, Q52KB6, Q561R3, Q5EA18, Q5I0E6, Q5R5T0, Q5RA37, Q5RCV3, Q5RL73, Q63505, Q7Z2T5, Q7ZWE3, Q80UU2, Q8BMI4, Q8BVY0, Q8C6C7, Q8IXW5, Q8K284, Q8K2X2, Q8N0S6, Q8N8B7, Q8VC34

Diamond homologs: Q1T7C0, Q28HN9, Q3U3S3, Q3ZAU7, Q5EA18, Q6DRD4, Q8N0S6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
CENPL	“form complex”	“CCAN complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 25 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Nucleosome assembly	5	125.2×	5e-08
Chromosome Maintenance	5	55.6×	2e-06
Deposition of new CENPA-containing nucleosomes at the centromere	5	41.7×	5e-06
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal	5	30.7×	1e-05
EML4 and NUDC in mitotic spindle formation	5	24.4×	4e-05
Resolution of Sister Chromatid Cohesion	5	22.8×	4e-05
RHO GTPases Activate Formins	5	20.4×	6e-05
Separation of Sister Chromatids	6	19.2×	1e-05

GO biological processes:

GO term	Partners	Fold	FDR
chromosome segregation	5	39.5×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	48
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

939 predictions. Top by Δscore:

Variant	Effect	Δscore
1:173807264:TA:T	donor_loss	1.0000
1:173807266:C:CT	donor_loss	1.0000
1:173811126:GCATA:G	donor_loss	1.0000
1:173811127:CATA:C	donor_loss	1.0000
1:173811128:ATAC:A	donor_loss	1.0000
1:173811129:TACC:T	donor_loss	1.0000
1:173811130:A:AC	donor_gain	1.0000
1:173811131:C:CC	donor_gain	1.0000
1:173811131:C:G	donor_loss	1.0000
1:173811303:CTGT:C	acceptor_gain	1.0000
1:173811304:TGT:T	acceptor_gain	1.0000
1:173811307:C:CC	acceptor_gain	1.0000
1:173811311:A:C	acceptor_gain	1.0000
1:173800517:AATCT:A	acceptor_loss	0.9900
1:173800518:ATC:A	acceptor_loss	0.9900
1:173800519:TCT:T	acceptor_loss	0.9900
1:173800520:C:CC	acceptor_gain	0.9900
1:173800520:C:T	acceptor_loss	0.9900
1:173800521:T:C	acceptor_loss	0.9900
1:173803093:T:TA	donor_gain	0.9900
1:173811131:CCTG:C	donor_gain	0.9900
1:173811194:T:TA	donor_gain	0.9900
1:173811305:GT:G	acceptor_gain	0.9900
1:173811307:CTG:C	acceptor_loss	0.9900
1:173811310:CA:C	acceptor_gain	0.9900
1:173823945:CGCTG:C	donor_gain	0.9900
1:173824866:G:GT	donor_gain	0.9900
1:173800516:GAAT:G	acceptor_gain	0.9800
1:173802960:AACCT:A	donor_loss	0.9800
1:173802961:ACC:A	donor_loss	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000035024 (1:173805825 C>G), RS1000060095 (1:173821555 T>G), RS1000197032 (1:173816946 T>A), RS1000208924 (1:173824302 CA>C), RS1000214011 (1:173813183 C>T), RS1000270310 (1:173816818 G>A,T), RS1000326277 (1:173817993 G>A,C), RS1000451026 (1:173810996 A>T), RS1000535921 (1:173818021 G>C), RS1000661229 (1:173823157 A>T), RS1000666403 (1:173816760 G>C), RS1000722333 (1:173824563 G>A), RS1000821014 (1:173812086 A>C), RS1000846198 (1:173805735 A>G), RS1000877074 (1:173810790 G>A,T)

Disease associations

OMIM: gene MIM:611503 | disease phenotypes: MIM:611105

GenCC curated gene-disease

Mondo (2): primary ovarian failure (MONDO:0005387), leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome (MONDO:0012622)

Orphanet (2): Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome (Orphanet:137898), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
C567009	Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
afuresertib	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
arsenite	affects binding, increases reaction	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
beta-methylcholine	affects expression	1
16-hydroxycleroda-3,13(14)-dien-15,16-olide	decreases expression	1
2-palmitoylglycerol	increases expression	1
abrine	increases expression	1
(+)-JQ1 compound	decreases expression	1
Dasatinib	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Arsenic	affects expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Calcitriol	decreases expression, affects cotreatment	1
Coumestrol	affects cotreatment, increases expression	1
Formaldehyde	decreases expression	1
Lucanthone	decreases expression	1
Methylcholanthrene	affects binding, increases reaction	1
N-Nitrosopyrrolidine	decreases expression	1
Oxygen	decreases expression	1
Ozone	affects expression, increases abundance	1
Testosterone	affects cotreatment, decreases expression	1
Dronabinol	affects expression	1
Tretinoin	decreases expression	1
Valproic Acid	decreases expression	1

Clinical trials (associated diseases)

80 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists